Abstract
Comprehensive genetic analyses have identified germline SDHB and FH gene mutations as predominant causes of metastatic paraganglioma and pheochromocytoma. However, some suspicious cases remain unexplained. In this study, we performed whole-exome sequencing of a paraganglioma exhibiting an SDHx-like molecular profile in the absence of SDHx or FH mutations and identified a germline mutation in the SLC25A11 gene, which encodes the mitochondrial 2-oxoglutarate/malate carrier. Germline SLC25A11 mutations were identified in six other patients, five of whom had metastatic disease. These mutations were associated with loss of heterozygosity, suggesting that SLC25A11 acts as a tumor-suppressor gene. Pseudohypoxic and hypermethylator phenotypes comparable with those described in SDHx- and FH-related tumors were observed both in tumors with mutated SLC25A11 and in Slc25a11Δ/Δ immortalized mouse chromaffin knockout cells generated by CRISPR-Cas9 technology. These data show that SLC25A11 is a novel paraganglioma susceptibility gene for which loss of function correlates with metastatic presentation.Significance: A gene encoding a mitochondrial carrier is implicated in a hereditary cancer predisposition syndrome, expanding the role of mitochondrial dysfunction in paraganglioma. Cancer Res; 78(8); 1914-22. ©2018 AACR.
Highlights
Pheochromocytomas and paragangliomas (PPGL) are neuroendocrine tumors with a very strong genetic component
We identified SLC25A11 as a new tumor-suppressor gene implicated in the predisposition to metastatic paraganglioma
malate–asparate shuttle (MAS) is composed of OGC (SLC25A11) and of two aspartate–glutamate carriers: CITRIN (SLC25A13) and ARALAR (SLC25A12; Fig. 2)
Summary
Pheochromocytomas and paragangliomas (PPGL) are neuroendocrine tumors with a very strong genetic component. Mutations in SDHx genes (SDHA, SDHB, SDHC, SDHD), encoding the tricarboxylic acid (TCA) cycle enzyme succinate dehydrogenase (or mitochondrial complex II) account for approximately 50% of the germline mutations identified in affected patients and cause multiple or metastatic PPGL [2]. These mutations abolish succinate dehydrogenase (SDH) activity, resulting in the accumulation of its substrate, succinate, which acts as an oncometabolite by inhibiting 2-oxoglutarate (2-OG)–dependent dioxygenases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.